ENTITY
Keymed Biosciences

Keymed Biosciences (2162 HK)

104
Analysis
Health Care • China
Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies for autoimmune diseases and oncology. Their pipeline includes over 50 programs, with key products like Kangyueda® (Stapokibart, CM310) for atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The company was founded in 2016 and is headquartered in Chengdu, China.
more
bearish•Transcenta
•22 Jul 2021 09:09

Pre-IPO Transcenta Holding - Insights on Pipeline and the Concerns

The article mainly analyzed Transcenta Holding in terms of its important product candidates MSB2311, TST001, TST005 and MSB0254,including the...

Logo
411 Views
Share
•07 Jul 2021 11:14

Keymed (康诺亚生物) IPO Trading: CDE Consultation Paper Marginally Positive for Pipeline

We look at the updates of Keymed IPO since our last note. Sentiments were positive for the deal as we have expected. The recent CDE consultation...

Logo
486 Views
Share
•04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
bearish•3SBio
•29 Jun 2021 09:09

3SBio Inc (1530.HK) - The Concerns and the Outlook

This insight mainly analyzed the potential reasons behind the decline in 3SBio Group's share price, the important products, the pipeline, the...

Logo
434 Views
Share
bullish•DiDi Global
•27 Jun 2021 11:39

ECM Weekly (27th June 2021) - Didi, Xpeng, Zylox, Dingdong, EBeauty, Chaoju Eye Care, Keymed Bio

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
x